How I treat late effects in adults after allogeneic stem cell transplantation

Blood

Volumn 117, Issue 11, 2011, Pages 3002-3009

  Savani, Bipin N ^a   Griffith, Michelle L ^b   Jagasia, Shubhada ^b   Lee, Stephanie J ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERGOCALCIFEROL; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; GLUCOSE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; METFORMIN; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RAPAMYCIN; SITAGLIPTIN; STEROID; SULFONYLUREA DERIVATIVE; VITAMIN D; WART VIRUS VACCINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIHYPERTENSIVE THERAPY; AVASCULAR NECROSIS; BLOOD GLUCOSE MONITORING; BRONCHIOLITIS OBLITERANS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC DIET; DIPHTHERIA; DRUG MEGADOSE; DYSLIPIDEMIA; EXTERNAL BEAM RADIOTHERAPY; GLUCOSE BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HAEMOPHILUS INFECTION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOGONADISM; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA A (H1N1); IONIZING RADIATION; IRON OVERLOAD; KIDNEY DYSFUNCTION; LUNG DISEASE; LUNG FUNCTION TEST; MENINGOCOCCOSIS; MYOPATHY; OSTEOLYSIS; PALPATION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERTUSSIS; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL; TETANUS; THYROID CANCER; THYROID DISEASE; THYROID FUNCTION TEST; UNSPECIFIED SIDE EFFECT; VACCINATION; WHOLE BODY RADIATION;

EID: 79953100650     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-263095     Document Type: Review

References (86)

1. Thomas ED. A history of bone marrow transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopoietic Cell Transplantation. West Sussex, UK: Wiley-Blackwell; 2009:3-7.
2. Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopoietic Cell Transplantation. West Sussex, UK: Wiley-Blackwell; 2009:15-21.
3. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617-1624.
4. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIB-MTR Summary Slides, 2010. http://www.cibmtr.org. Accessed August 17, 2010.
5. Lee SJ. Late critical problems in transplantation: an historical perspective. Hematology Am Soc Hematol Educ Program. 2008:124.
6. Flowers MED, Deeg HJ. Delayed nonmalignant complications after hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopoietic Cell Transplantation. West Sussex, UK: Wiley-Blackwell; 2009:1620-1637.
7. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784-3792. (Pubitemid 350159650)
8. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101(9):3373-3385. (Pubitemid 36857917)
9. Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood. 2004;104(6):1898-1906.
10. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011-1016.
11. Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol. 2008; 142(1):11-26. (Pubitemid 351784478)
12. Couriel D, Carpenter PA, Cutler C, et al. Ancillarytherapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12(4):375-396.
13. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175-1183.
14. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation: Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med. 1999;131(10): 738-744.
15. Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood MarrowTransplant. 2007;13(10): 1121-1134. (Pubitemid 47413023)
16. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19(2):464-471. (Pubitemid 32112860)
17. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2010;117(1): 316-322.
18. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood. 2008;111(2):939-944.
19. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897-904. (Pubitemid 27137189)
20. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105(10):3802-3811. (Pubitemid 40662691)
21. Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006;24(7):1119-1126. (Pubitemid 46638809)
22. Savani BN, Goodman S, Barrett AJ. Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin Cancer Res. 2009;15(7):2219-2221.
23. Savani BN, Stratton P, Shenoy A, et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation: implications for screening and HPV vaccination. Biol Blood Marrow Transplant. 2008;14(9):1072-1075.
24. Oeffinger KC, Ford JS, Moskowitz CS, et al. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA. 2009;301(4):404-414.
25. Ohba K, Nishizawa S, Matsushita A, et al. High incidence of thyroid cancer in focal thyroid incidentaloma detected by 18F-fluorodexyglucose positron emission tomography in relatively young healthy subjects: results of 3-year follow-up. Endocr J. 2010;57(5):395-401.
26. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-1214.
27. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2(8552):175-178. (Pubitemid 17091848)
28. Corre E, Carmagnat M, Busson M, et al. Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections. Haematologica. 2010;95(6): 1025-1029.
29. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521-526.
30. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
31. Clifton C, Vaughan LA, Lucid C, et al. Vaccinations efficacy in long-term survivors after allogeneic stem cell transplantation: implication of repeat vaccinations and documenting vaccination efficacy. ASH Annual Meeting Abstracts. 2009; 114:3330.
32. Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines. 2010; 9(3):229-236.
33. Advisory Committee on Immunization Practices. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:258-261.
34. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009; 302(3):306-314.
35. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(7):749-759. (Pubitemid 46902446)
36. Savani BN, Montero A, Wu C, et al. Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(3):223-230. (Pubitemid 40287921)
37. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560-565. (Pubitemid 43956361)
38. Savani BN, Montero A, Srinivasan R, et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(12): 1261-1269. (Pubitemid 44858271)
39. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: an increasingly recognized manifestation of chronic graft-verus-host disease. Biol Blood Marrow Transplant. 2010;16(1)[suppl]:S106-S114.
40. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168(2):208-214. (Pubitemid 36920975)
41. Santo Tomas LH, Loberiza FR Jr, Klein JP, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005;128(1):153-161. (Pubitemid 40994467)
42. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation: clinical presentation and course. Ann Intern Med. 1989;111(5):368-376. (Pubitemid 19231290)
43. Bashoura L, Gupta S, Jain A, et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(1):63-67.
44. Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2010;29(5): 531-537.
45. Griffith ML, Jagasia M, Jagasia SM. Diabetes mellitus after hematopoietic stem cell transplantation. Endocr Pract. 2010;16(4):699-706.
46. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109(4):1765-1772. (Pubitemid 46239613)
47. Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(9):1100-1107.
48. Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood. 2010;116(8):1197-1204.
49. Armenian SH, Sun CL, Mills G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16(8):1138-1144.
50. Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol. 2006;17(7):1995-2005. (Pubitemid 44036184)
51. Tichelli A, Passweg J, Wojcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93(8):1203-1210.
52. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007; 110(9):3463-3471. (Pubitemid 350106343)
53. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752.
54. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769-1778. (Pubitemid 40923091)
55. Annaloro C, Usardi P, Airaghi L, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(9):797-804. (Pubitemid 351696344)
56. Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009;43(1):49-54.
57. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12(2):138-151. (Pubitemid 43138009)
58. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6): 1206-1252. (Pubitemid 37553153)
59. Hoffmeister PA, Hingorani SR, Storer BE, Baker KS, Sanders JE. Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16(4):515-524.
60. Savani BN, Koklanaris EK, Le Q, et al. Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009;15(3):377-381.
61. Somali M, Mpatakoias V, Avramides A, et al. Thyroid dysfunction in adult long-term survivors after hemapoeitic stem-cell transplantation (HSCT). Horm Metab Res. 2005;37(8):494-499. (Pubitemid 41306399)
62. Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood. 2009;113(2):306-308.
63. Cohen A, Bekassy AN, Gaiero A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant. 2008; 41[suppl 2]:S43-S48. (Pubitemid 351864707)
64. McDermott MT, Haugen BR, Lezotte DC, Seggelke S, Ridgway EC. Management practices among primary care physicians and thyroid specialists in the care of hypothyroid patients. Thyroid. 2001;11(8):757-764. (Pubitemid 32762713)
65. Rovo A, Tichelli A, Passweg JR, et al. Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood. 2006;108(13):1100-1105. (Pubitemid 44154651)
66. Savani BN, Kozanas E, Shenoy A, Barrett AJ. Recovery of spermatogenesis after total-body irradiation. Blood. 2006;108(13):4292-4293.
67. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350(5):482-492. (Pubitemid 38133769)
68. Nelson LM. Clinical practice: primary ovarian insufficiency. N Engl J Med. 2009;360(6):606-614.
69. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692.
70. Armand P, Kim HT, Rhodes J, et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2010 Sep 17 [Epub ahead of print].
71. Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2010;16(6):832-837.
72. Rose C, Ernst O, Hecquet B, et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long-term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica. 2007;92(6):850-853. (Pubitemid 350155314)
73. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83(11):858-861.
74. Yao S, McCarthy PL, Dunford LM, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant. 2008;41(4):393-398. (Pubitemid 351330735)
75. Savani BN, Donohue T, Kozanas E, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(5):517-520. (Pubitemid 46585937)
76. Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6(2A):165-174.
77. Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab. 2009;94(5):1483-1490.
78. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19): 1761-1771.
79. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol. 1997;97(4):865-870. (Pubitemid 27321389)
80. McAvoy S, Baker KS, Mulrooney D, et al. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16(12):1231-1236.
81. Campbell S, Sun CL, Kurian S, et al. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer. 2009;115(18):4127-4135.
82. Hingorani S. Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant. Pediatr Nephrol. 2008;23(6):879-888.
83. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer. 2008;113(7):1580-1587.
84. Abboud I, Porcher R, Robin M, et al. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(10):1251-1257.
85. Lopez Santi RG, Valeff EC, Duymovich CR, et al. Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study. Coron Artery Dis. 2005;16:423-429. (Pubitemid 41527449)
86. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for anti-inflammatory actions. Pharmacotherapy. 2005;25: 1213-1229. (Pubitemid 41244813)